Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Muser

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Journal of Comparative Effectiveness Research|July 15, 2015
Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patientsYongling Xiao, Erik Muser, Marie-Hélène Lafeuille, et al.
Clinical Therapeutics|October 18, 2011
Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventionsErin Bagalman, Erik Muser, Jiyoon C Choi, et al.
Journal of Medical Economics|September 7, 2013
Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychoticsMarie-Hélène Lafeuille, Jonathan Gravel, Patrick Lefebvre, et al.
Journal of Medical Economics|February 29, 2024
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United StatesDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Journal of Medical Economics|April 9, 2015
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvementErik Muser, Chris M Kozma, Carmela J Benson, et al.
Crohn'S & Colitis 360|February 13, 2023
Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional AgentsDominic Pilon, Zhijie Ding, Erik Muser, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 20, 2015
Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychoticsMarie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Fortier, et al.
Journal of Health Economics and Outcomes Research|September 13, 2024
Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology SettingBenjamin H Lowentritt, Carmine Rossi, Erik Muser, et al.
Journal of Comparative Effectiveness Research|September 25, 2014
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidenceElaine H Morrato, Joe Parks, Elizabeth J Campagna, et al.
Journal of Managed Care & Specialty Pharmacy|July 1, 2024
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United StatesDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Journal of Comparative Effectiveness Research|July 15, 2015
Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patientsYongling Xiao, Erik Muser, Marie-Hélène Lafeuille, et al.
Clinical Therapeutics|October 18, 2011
Health care resource utilization and costs in a commercially insured population of patients with bipolar disorder type I and frequent psychiatric interventionsErin Bagalman, Erik Muser, Jiyoon C Choi, et al.
Journal of Medical Economics|September 7, 2013
Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychoticsMarie-Hélène Lafeuille, Jonathan Gravel, Patrick Lefebvre, et al.
Journal of Medical Economics|February 29, 2024
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United StatesDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Journal of Medical Economics|April 9, 2015
Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvementErik Muser, Chris M Kozma, Carmela J Benson, et al.
Crohn'S & Colitis 360|February 13, 2023
Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional AgentsDominic Pilon, Zhijie Ding, Erik Muser, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 20, 2015
Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychoticsMarie-Hélène Lafeuille, Amanda Melina Grittner, Jonathan Fortier, et al.
Journal of Health Economics and Outcomes Research|September 13, 2024
Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology SettingBenjamin H Lowentritt, Carmine Rossi, Erik Muser, et al.
Journal of Comparative Effectiveness Research|September 25, 2014
Comparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidenceElaine H Morrato, Joe Parks, Elizabeth J Campagna, et al.
Journal of Managed Care & Specialty Pharmacy|July 1, 2024
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United StatesDeborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
Pageof 5